Belviq
Drug
Eisai Inc.
Total Payments
$55.3M
Transactions
69,786
Doctors
7,779
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.8M | 177 | 3 |
| 2019 | $4.1M | 5,121 | 2,220 |
| 2018 | $26.2M | 28,575 | 4,546 |
| 2017 | $23.2M | 35,913 | 4,634 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $44.7M | 48,748 | 80.7% |
| Consulting Fee | $10.4M | 82 | 18.7% |
| Food and Beverage | $274,140 | 18,443 | 0.5% |
| Education | $28,577 | 2,433 | 0.1% |
| Travel and Lodging | $16,553 | 80 | 0.0% |
Payments by Type
Research
$44.7M
48,748 transactions
General
$10.7M
21,038 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | Eisai Inc. | $39.2M | 0 |
| A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | Eisai Inc. | $3.1M | 0 |
| A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | Eisai Inc. | $1.8M | 0 |
| Develop & Manage Healthy Lifestyle Program | Eisai Inc. | $328,929 | 0 |
| Randomized controlled trial of lifestyle intervention and Belviq for weight loss maintenance | Eisai Inc. | $140,923 | 0 |
| Lorcaserin in Obesity: Identification of CNS targets using fMRI | Eisai Inc. | $39,719 | 0 |
| Real World Patient Experience w/ Lorcaserin for Weight Management) | Eisai Inc. | $39,605 | 0 |
| A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | EISAI INC. | $11,692 | 0 |
Top Doctors Receiving Payments for Belviq — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Raymond Plodkowski | Endocrinology, Diabetes & Metabolism | San Diego, CA | $604.23 | 48 |
| , MD | Family Medicine | Atlanta, GA | $573.46 | 41 |
| , MD | Internal Medicine | Libertyville, IL | $508.16 | 43 |
| , M.D | Internal Medicine | Poway, CA | $498.53 | 33 |
| , M.D | Internal Medicine | West Hempstead, NY | $495.36 | 33 |
| , M.D | Internal Medicine | East Meadow, NY | $480.16 | 32 |
| , D.O | Internal Medicine | Bethpage, NY | $430.37 | 20 |
| , DO | Cardiovascular Disease | Farmington Hills, MI | $426.47 | 36 |
| , MD | Internal Medicine | Glenview, IL | $416.98 | 27 |
| , MD | Internal Medicine | Webster, TX | $410.19 | 30 |
| , DO | Family Medicine | Setauket, NY | $403.91 | 25 |
| , D.O | Obstetrics & Gynecology | Bala Cynwyd, PA | $397.96 | 30 |
| , MD | Internal Medicine | Glenview, IL | $393.62 | 26 |
| , D.O | Family Medicine | Houston, TX | $373.59 | 26 |
| , M.D | Internal Medicine | San Diego, CA | $367.40 | 26 |
| , DO | Internal Medicine | Smithtown, NY | $359.71 | 21 |
| , DO | Family Medicine | Island Park, NY | $358.61 | 17 |
| , MD | Pediatrics | Louisville, KY | $339.81 | 29 |
| , MD | Internal Medicine | New York, NY | $339.63 | 24 |
| , MD | Internal Medicine | Houston, TX | $339.54 | 24 |
| , MD | Gastroenterology | White Plains, NY | $339.29 | 20 |
| , DO | Family Medicine | Island Park, NY | $338.20 | 16 |
| , MD | Internal Medicine | Libertyville, IL | $336.04 | 29 |
| , M.D | Obesity Medicine | Germantown, TN | $334.45 | 21 |
| , M.D | Endocrinology, Diabetes & Metabolism | Atlanta, GA | $331.48 | 28 |
Ad
Manufacturing Companies
- Eisai Inc. $54.8M
- EISAI INC. $539,983
Product Information
- Type Drug
- Total Payments $55.3M
- Total Doctors 7,779
- Transactions 69,786
About Belviq
Belviq is a drug associated with $55.3M in payments to 7,779 healthcare providers, recorded across 69,786 transactions in the CMS Open Payments database. The primary manufacturer is Eisai Inc..
Payment data is available from 2017 to 2020. In 2020, $1.8M was paid across 177 transactions to 3 doctors.
The most common payment nature for Belviq is "Unspecified" ($44.7M, 80.7% of total).
Belviq is associated with 8 research studies, including "A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors" ($39.2M).